Herein, we tested the hypothesis that UGT1A1 variants (UGT1A1*28 and UGT1A1*6) are associated with higher plasma bilirubin levels and subsequently protect against NAFLD, using a Mendelian randomization approach. This evidence concerns the gene UGT1A1 and metabolic dysfunction-associated steatotic liver disease.